ORIGINAL RESEARCH article
Front. Nanotechnol.
Sec. Biomedical Nanotechnology
This article is part of the Research TopicAdvancements in Polymer- and Lipid-Based Nanoparticles for Enhancing Drug Solubility, Stability, and BioavailabilityView all articles
Dual - Functional cRGD/pH - Sensitive Liposomes Loaded with Sorafenib: A Novel Therapeutic Approach for Hepatocellular Carcinoma
Provisionally accepted
- Shanghai Fifth People's Hospital, Fudan University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Sorafenib, a first-line treatment for advanced hepatocellular carcinoma (HCC), is severely limited by its low oral bioavailability, lack of tumor specificity, and dose-limiting systemic adverse effects. Nanocarrier-based delivery systems, particularly liposomes, offer a promising strategy to overcome these limitations. Methods: We developed a multifunctional liposomal system co-modified with a cyclic RGD (cRGD) peptide and pH-sensitive components (cholesteryl hemisuccinate, CHEMS) for sorafenib delivery (cRGD-pH-Lipo/Sor). The physicochemical properties, drug release profile, stability, and biosafety of this formulation were thoroughly characterized. Its targeting efficiency, cellular uptake, and antitumor efficacy were evaluated in both in vitro (Huh7 and HepG2 cells) and in vivo (Huh7-xenograft nude mice) models using techniques including HPLC, fluorescence imaging, CCK-8 and in vivo imaging system (IVIS). Results: The optimized cRGD-pH-Lipo/Sor exhibited a uniform particle size distribution(116.73±1.07 nm, polydispersity index of 0.224±0.0017), negative zeta potential (- 22.2±3.50 mV), high encapsulation efficiency (84.1%), and a desirable pH-responsive drug release profile (cumulative release: 73.2% at pH 5.0 vs. 38.4% at pH 7.4). In vitro, cRGD-pH-Lipo/Sor demonstrated significantly enhanced cellular uptake in HCC cells compared to free sorafenib and non-targeted liposomes, attributable to cRGD-mediated active targeting and pH-triggered release. In vivo imaging and biodistribution studies confirmed the superior tumor accumulation of cRGD-pH-Lipo. Most importantly, in a xenograft mouse model, cRGD-pH-Lipo/Sor achieved the most potent tumor growth inhibition without inducing significant systemic toxicity, as evidenced by body weight monitoring, serum biochemical analysis, and histopathological examination. Conclusion: The cRGD-modified, pH-sensitive liposomal platform effectively addresses key pharmacological drawbacks of sorafenib. It enhances tumor-targeted delivery, promotes intracellular drug release, and significantly improves the therapeutic index, presenting a promising novel strategy for the systemic treatment of advanced HCC.
Keywords: Chems, cRGD peptide, HCC, Liposome, Sorafenib
Received: 04 Dec 2025; Accepted: 05 Feb 2026.
Copyright: © 2026 Yang, Zhou, Liang, Liu and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guangchun Sun
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.